MX2007005176A - Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents. - Google Patents

Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents.

Info

Publication number
MX2007005176A
MX2007005176A MX2007005176A MX2007005176A MX2007005176A MX 2007005176 A MX2007005176 A MX 2007005176A MX 2007005176 A MX2007005176 A MX 2007005176A MX 2007005176 A MX2007005176 A MX 2007005176A MX 2007005176 A MX2007005176 A MX 2007005176A
Authority
MX
Mexico
Prior art keywords
carboxyamide
triazoles
pyrazoles
substituted
antiviral agents
Prior art date
Application number
MX2007005176A
Other languages
Spanish (es)
Inventor
Huw M Nash
Hugh Y Zhu
Alan B Cooper
Jagdish A Desai
James J-S Wang
Viyyoor Moopil Girijavallabhan
Gerald W Shipps Jr
Patrick J Curran
D Allen Annis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2007005176A publication Critical patent/MX2007005176A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

The present invention provides compounds of formula I wherein X, Y, R1-R7 areas defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided. (I).
MX2007005176A 2004-10-29 2005-10-26 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents. MX2007005176A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62317304P 2004-10-29 2004-10-29
PCT/US2005/038796 WO2006050034A1 (en) 2004-10-29 2005-10-26 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents

Publications (1)

Publication Number Publication Date
MX2007005176A true MX2007005176A (en) 2007-06-25

Family

ID=35907008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005176A MX2007005176A (en) 2004-10-29 2005-10-26 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents.

Country Status (11)

Country Link
US (1) US7425640B2 (en)
EP (1) EP1814860B1 (en)
JP (2) JP4762995B2 (en)
CN (1) CN101087762A (en)
AT (1) ATE432922T1 (en)
CA (1) CA2585373A1 (en)
DE (1) DE602005014804D1 (en)
ES (1) ES2326750T3 (en)
HK (1) HK1104290A1 (en)
MX (1) MX2007005176A (en)
WO (1) WO2006050034A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361672B2 (en) * 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
WO2008076904A1 (en) 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
BRPI0809366B8 (en) 2007-03-28 2021-05-25 Harvard College substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2765263C (en) * 2009-06-12 2016-07-12 Jong Hoon Kim Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (en) 2011-10-18 2018-12-04 爱勒让治疗公司 Peptidomimetic macrocyclic compound
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (en) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド Disubstituted amino acids and methods for their preparation and use
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
MX2017011834A (en) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
WO2016161021A1 (en) * 2015-03-30 2016-10-06 Prosetta Antiviral, Inc. N-methyl pyrazoles
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
CN111777559B (en) * 2019-04-23 2021-11-09 苏州大学 Method for preparing polysubstituted pyrazole based on terminal alkyne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034127A1 (en) * 2000-07-21 2004-02-04 Schering Corp IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US7209491B2 (en) * 2002-06-28 2007-04-24 Nokia Corporation Method and system for transmitting data in a packet based communication network
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE60329529D1 (en) * 2002-12-23 2009-11-12 Sanofi Aventis Deutschland Pyrazoline Derivatives as Factor Xa Inhibitors
JP2007530516A (en) 2004-03-26 2007-11-01 スミスクライン・ビーチャム・コーポレイション 4-Carboxypyrazole derivatives useful as antiviral agents

Also Published As

Publication number Publication date
EP1814860A1 (en) 2007-08-08
US20060111411A1 (en) 2006-05-25
JP4762995B2 (en) 2011-08-31
DE602005014804D1 (en) 2009-07-16
JP2011068681A (en) 2011-04-07
CN101087762A (en) 2007-12-12
ES2326750T3 (en) 2009-10-19
EP1814860B1 (en) 2009-06-03
US7425640B2 (en) 2008-09-16
ATE432922T1 (en) 2009-06-15
HK1104290A1 (en) 2008-01-11
WO2006050034A1 (en) 2006-05-11
JP2008518919A (en) 2008-06-05
CA2585373A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
MX2007005176A (en) Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents.
UA91255C2 (en) Antiviral nucleosides
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2004009020A3 (en) Pyrrolopyrimidine thionucleoside analogs as antivirals
EP1687018A4 (en) Hepatitis c virus inhibitors
MY146123A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
ATE389656T1 (en) PYRAZOLO(1,5-A)PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS
MY140680A (en) Hepatitis c virus inhibitors
WO2005054430A3 (en) Hepatitis c virus inhibitors
WO2007020193A3 (en) Antiviral phosphoramidates of 4 ' -substituted pronucleotides
TW200716133A (en) Anti-infective agents
IL177537A (en) Viral polymerase inhibitors and pharmaceutical compositions comprising them
WO2006065335A3 (en) Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
MXPA05007754A (en) Viral polymerase inhibitors.
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
WO2009069095A3 (en) Antiviral nucleoside compounds
EP1663105A4 (en) Cycloalkyl heterocycles for treating hepatitis c virus
MX2007005177A (en) Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents.

Legal Events

Date Code Title Description
FG Grant or registration